X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117) 117
benzoxazines (112) 112
index medicus (108) 108
hiv infections - drug therapy (74) 74
benzoxazine (67) 67
female (63) 63
male (61) 61
benzoxazin (53) 53
benzoxazines - therapeutic use (49) 49
polymer science (46) 46
adult (45) 45
analysis (45) 45
polymers (42) 42
anti-hiv agents - therapeutic use (41) 41
benzoxazines - administration & dosage (41) 41
hiv (37) 37
polybenzoxazines (37) 37
efavirenz (36) 36
pharmacology & pharmacy (35) 35
polymerization (35) 35
reverse transcriptase inhibitors - therapeutic use (32) 32
animals (29) 29
drug therapy (29) 29
anti-hiv agents - economics (28) 28
antiviral agents (28) 28
reverse transcriptase inhibitors - economics (26) 26
benzoxazines - adverse effects (24) 24
infectious diseases (24) 24
monomers (23) 23
treatment outcome (23) 23
anti-hiv agents - administration & dosage (22) 22
benzoxazines - chemistry (22) 22
highly active antiretroviral therapy (22) 22
middle aged (22) 22
benzoxazines - economics (21) 21
chemistry (21) 21
drug therapy, combination (20) 20
hiv infection (20) 20
kalorimetrie (20) 20
oxazines - economics (20) 20
polymer (20) 20
adolescent (19) 19
chemistry, applied (19) 19
hiv infections - economics (19) 19
monomer (19) 19
oxazines - therapeutic use (19) 19
ring-opening polymerization (19) 19
thermal properties (19) 19
anti-hiv agents - adverse effects (18) 18
benzoxazines - pharmacology (18) 18
curing (18) 18
research (18) 18
resins (18) 18
therapy (18) 18
chemistry, multidisciplinary (17) 17
dosage and administration (17) 17
human immunodeficiency virus--hiv (17) 17
nanocomposites (17) 17
time factors (17) 17
viral load (17) 17
aids (16) 16
benzoxazines - pharmacokinetics (16) 16
cd4 lymphocyte count (16) 16
mechanical properties (16) 16
young adult (16) 16
adherence (15) 15
antiretroviral drugs (15) 15
crosslinking (15) 15
derivatives (15) 15
drug combinations (15) 15
hiv infections - virology (15) 15
antiretroviral therapy (14) 14
child (14) 14
cost-benefit analysis (14) 14
epoxy resins (14) 14
health aspects (14) 14
komposit (14) 14
materials science, composites (14) 14
nevirapine - therapeutic use (14) 14
pharmacokinetics (14) 14
polybenzoxazine (14) 14
research article (14) 14
thermal stability (14) 14
thermosets (14) 14
united states (14) 14
usage (14) 14
acid (13) 13
chemistry, organic (13) 13
composites (13) 13
engineering, chemical (13) 13
fourier transforms (13) 13
materials science, multidisciplinary (13) 13
mechanical-properties (13) 13
physiological aspects (13) 13
behavior (12) 12
cardanol (12) 12
chemical synthesis (12) 12
dose-response relationship, drug (12) 12
drug administration schedule (12) 12
drugs (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 2013, Volume 158, Issue 2, pp. 84 - 92
Journal Article
Nature, ISSN 0028-0836, 04/2017, Volume 544, Issue 7648, pp. 20 - 22
Genetics, Medical - economics | HIV Infections - epidemiology | Humans | Benzoxazines - metabolism | Charities - economics | Diabetes Mellitus, Type 2 - epidemiology | Reverse Transcriptase Inhibitors - adverse effects | Neoplasms - therapy | Kidney Diseases - epidemiology | Trypanosomiasis, African - genetics | Anti-HIV Agents - metabolism | Genetic Predisposition to Disease | Benzoxazines - administration & dosage | Genetics, Medical - trends | Kidney Diseases - economics | Heterocyclic Compounds, 3-Ring - therapeutic use | Public Health - trends | Genomics - economics | Africa - epidemiology | Lipoproteins, HDL - genetics | United States | Diabetes Mellitus, Type 2 - genetics | National Institutes of Health (U.S.) - economics | Precision Medicine - economics | Genome-Wide Association Study - statistics & numerical data | Public Health - economics | Kidney Diseases - genetics | Stroke - genetics | Neoplasms - genetics | Apolipoproteins - genetics | Trypanosomiasis, African - epidemiology | Africa - ethnology | Anti-HIV Agents - therapeutic use | Neoplasms - radiotherapy | Stroke - epidemiology | African Continental Ancestry Group - genetics | Reverse Transcriptase Inhibitors - therapeutic use | European Continental Ancestry Group - genetics | Anti-HIV Agents - adverse effects | HIV Infections - genetics | Benzoxazines - adverse effects | Benzoxazines - therapeutic use | Apolipoprotein L1 | Kidney Diseases - therapy | Polymorphism, Single Nucleotide - genetics | Precision Medicine - trends | HIV Infections - drug therapy | Reverse Transcriptase Inhibitors - metabolism | Genomics - trends | Economic aspects | Social aspects | Genomics | Public health
Journal Article
International Journal of Chronic Obstructive Pulmonary Disease, ISSN 1176-9106, 10/2016, Volume 11, Issue 1, pp. 2191 - 2201
PURPOSE: The fixed-dose dual bronchodilator combination (FDC) of tiotropium and olodaterol showed increased effectiveness regarding lung function and... 
Cost–utility | Budget impact | Health economics | Cost-effectiveness | COPD | cost-effectiveness | UTILITY ANALYSIS | DAILY MAINTENANCE BRONCHODILATOR | SAFETY | INHALED CORTICOSTEROIDS | RISK | budget impact | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | PLUS OLODATEROL | EXACERBATIONS | ECONOMIC-IMPACT | RESPIMAT(R) | cost-utility | health economics | Bronchodilator Agents - therapeutic use | Drug Costs | Pulmonary Disease, Chronic Obstructive - mortality | Markov Chains | Cholinergic Antagonists - economics | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Models, Economic | Forced Expiratory Volume | Netherlands | Time Factors | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Tiotropium Bromide - therapeutic use | Budgets | Pulmonary Disease, Chronic Obstructive - economics | Cholinergic Antagonists - therapeutic use | Quality-Adjusted Life Years | Severity of Illness Index | Bronchodilator Agents - economics | Treatment Outcome | Lung - physiopathology | Disease Progression | Benzoxazines - therapeutic use | Tiotropium Bromide - economics | Medication Adherence | Adrenergic beta-2 Receptor Agonists - economics | Cost-Benefit Analysis | Lung - drug effects | Aged | Benzoxazines - economics | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Markov processes | Economic aspects | Lung diseases, Obstructive | Analysis
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, p. e0198447
Background Nearly all newly infected children acquire Human Immunodeficiency virus (HIV) via mother-to-child transmission (MTCT) during pregnancy, labour or... 
CONSISTENCY | INTERVENTIONS | EFFICACY | INCONSISTENCY | MULTIDISCIPLINARY SCIENCES | PRETERM BIRTH | PREGNANT-WOMEN | RISK | 1ST TRIMESTER | COHORT | EXPOSURE | Anti-HIV Agents - economics | Nevirapine - economics | Humans | Infant | Nevirapine - adverse effects | Lamivudine - adverse effects | Stavudine - economics | Congenital Abnormalities | Drug Therapy, Combination - adverse effects | Stavudine - adverse effects | Zidovudine - economics | Female | Network Meta-Analysis | Child | Infant, Newborn | Infant, Low Birth Weight | Abnormalities, Drug-Induced - epidemiology | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Drug Therapy, Combination - economics | Pregnancy | Pregnancy Complications, Infectious - drug therapy | Stillbirth - epidemiology | HIV Infections - drug therapy | Lamivudine - economics | Infectious Disease Transmission, Vertical - statistics & numerical data | Perinatal Care - economics | Benzoxazines - economics | Infectious Disease Transmission, Vertical - prevention & control | Antiviral agents | Maternal-fetal exchange | Patient outcomes | Labor, Complicated | HIV patients | Birth defects | Risk factors | Prevention | Complications and side effects | Maternal health services | Disease transmission | Pregnant women | Dosage and administration | Drug therapy | Health aspects | Methods | Drugs | Nevirapine | Congenital defects | Clinical trials | Viruses | Risk | Systematic review | Infants | Stavudine | Efavirenz | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Safety | Children | Indinavir | Risk reduction | Lamivudine | Breast feeding | Patients | Antiretroviral therapy | Womens health | Birth weight | Bayesian analysis | Zidovudine | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Value in Health, ISSN 1098-3015, 2011, Volume 14, Issue 5, pp. 657 - 664
Abstract Objective To estimate the cost-effectiveness of once-daily tenofovir/emtricitabine compared with twice-daily zidovudine/lamivudine and once-daily... 
Internal Medicine | AIDS | Markov model | cost-effectiveness analysis | drug combinations | EMTRICITABINE | COLLABORATIVE ANALYSIS | RANDOMIZED-TRIAL | MORTALITY-RATES | HUMAN-IMMUNODEFICIENCY-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | ACTIVE ANTIRETROVIRAL THERAPY | HEALTH CARE SCIENCES & SERVICES | SPARING REGIMENS | HEALTH POLICY & SERVICES | ECONOMICS | QUALITY-OF-LIFE | CELL COUNT | Drug Costs | Anti-HIV Agents - economics | United States - epidemiology | Markov Chains | HIV Infections - economics | Humans | Male | Models, Economic | Health Services Research | Viral Load | Adenine - economics | Cost Savings | Dideoxynucleosides - economics | Tenofovir | Zidovudine - economics | Time Factors | HIV Infections - diagnosis | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - mortality | Reverse Transcriptase Inhibitors - therapeutic use | Emtricitabine | Quality-Adjusted Life Years | Organophosphonates - economics | Adenine - analogs & derivatives | Reverse Transcriptase Inhibitors - economics | Treatment Outcome | CD4 Lymphocyte Count | Clinical Trials as Topic | Deoxycytidine - economics | Benzoxazines - therapeutic use | Antiretroviral Therapy, Highly Active | Outcome and Process Assessment (Health Care) - economics | Cost-Benefit Analysis | HIV Infections - drug therapy | Lamivudine - economics | Benzoxazines - economics | Deoxycytidine - analogs & derivatives
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2008, Volume 30, Issue 2, pp. 372 - 381
Journal Article
International Journal of COPD, ISSN 1176-9106, 10/2015, Volume 10, Issue 1, pp. 2347 - 2356
Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive decline in lung function, is considered to be a leading... 
Bronchodilators | Tiotropium | Long-acting β2 agonists | Chronic obstructive pulmonary disease | Long-acting muscarinic antagonist | Olodaterol | MANAGEMENT | GOLD 2-4 | EFFICACY | HYPERINFLATION | bronchodilators | long-acting beta agonists | INHALER | olodaterol | tiotropium | SALMETEROL | ONCE-DAILY TIOTROPIUM | RESPIRATORY SYSTEM | RESPIMAT(R) | FIXED-DOSE COMBINATION | long-acting muscarinic antagonist | chronic obstructive pulmonary disease | COPD | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Drug Costs | Bronchodilator Agents - administration & dosage | Cholinergic Antagonists - economics | Humans | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Tiotropium Bromide - pharmacokinetics | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Adrenergic beta-2 Receptor Agonists - adverse effects | Benzoxazines - pharmacokinetics | Bronchodilator Agents - adverse effects | Cholinergic Antagonists - adverse effects | Pulmonary Disease, Chronic Obstructive - economics | Cholinergic Antagonists - pharmacokinetics | Bronchodilator Agents - economics | Pulmonary Disease, Chronic Obstructive - diagnosis | Benzoxazines - administration & dosage | Drug Administration Schedule | Tiotropium Bromide - adverse effects | Administration, Inhalation | Benzoxazines - adverse effects | Treatment Outcome | Lung - physiopathology | Cholinergic Antagonists - administration & dosage | Drug Synergism | Tiotropium Bromide - economics | Adrenergic beta-2 Receptor Agonists - economics | Bronchodilator Agents - pharmacokinetics | Cost-Benefit Analysis | Lung - drug effects | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Benzoxazines - economics | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Dosage and administration | Research | Drug therapy
Journal Article
Journal Article
Journal Article
Journal Article
Polymer Chemistry, ISSN 1759-9954, 01/2018, Volume 9, Issue 47, pp. 5566 - 5571
A novel octylphosphonic acid (OPA)-catalyzed, high-efficiency, three-component polymerization system involving benzoxazines, odorless isocyanides, and water... 
Economics | Polyamide resins | Reaction time | Polymerization | Benzoxazines | Chemical synthesis | Substrates | Room temperature
Journal Article
International Journal of Gynecology & Obstetrics, ISSN 0020-7292, 03/2012, Volume 116, Issue 3, pp. 219 - 222
Journal Article
Journal Article
Expert Review of Anti-infective Therapy, ISSN 1478-7210, 01/2016, Volume 14, Issue 1, pp. 19 - 27
Journal Article